Lupin, Inc.

Ranbaxy Laboratories, Inc.

Council of Scientific and Industrial Research

Neelima Sinha

Rajender Kumar Kamboj

Venkata Poornapragnacharyulu Palle

Sanjay Kumar Jain

Navnath Popat Karche

Nitya Anand

Nageswara Rao Irlapati

Anita Mehta

Anil Kumar Saxena

Anil Kashiram Hajare

Gourhari Jana

Gokul Keruji Deshmukh

Ajay Ramchandra Tilekar

Vijay Pandurang Karche

Sudershan Kumar Arora

Rakesh Kumar Sinha

Santosh Madhukar Jachak

Zubair Abdul Wajid Shaikh

Shridhar Keshav Adurkar

Sanjay Pralhad Kurhade

Jang Bahadur Gupta

Prathap Sreedharan Nair

Nilesh Raghunath Khedkar

Shankar Ajay

Madhur Ray

Dnyaneshwar Changdeo Bhanage

Ram Shankar Upadhayaya

Sachchidanand Sachchidanand

Mangal Prasad Dubey

Ram Mohan Saxena

Gyanendra Kumar Patnaik, Deceased

Baban Rupaji Thube

Kiran Chandrashekhar Kulkarni

Rajan Goel

Anita Chugh

Majid Bashir Sayyed

Gagan Kukreja

Sai Kumar Chakka

Azmi Reddy

Pravin Patil

K H Sreedhara Swamy

Ravindra Babanrao Jape

Rahul Shripad Nandurdikar

Ram Shankar Upadhyaya

Laxminarayan G Hegde

Bikramjit Singh Lairikyengbam

Jang Bahadurgupta

Firoj Aftab Raje

Arun Rangnath Jagdale

Girish Dhanraj Hatnapure

Nabendu Saha

The present invention relates to compounds of Formula (I), along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

Oxazoline and isoxazoline derivatives as CRAC modulators

The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators.

Chromane and chromene derivatives and their use as CRAC modulators

The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CRor N; Y is CRor N; L is selected from &#x2014;NRC(O)&#x2014;, &#x2014;C(O)NR&#x2014; and &#x2014;NRCRR&#x2014;; Rand Rare independently hydrogen, halogen or substituted or unsubstituted alkyl; ring E is selected from the Formula (i) to (vii).

Substituted heterocyclic compounds as CRAC modulators

Disclosed are compounds of the Formula (I), wherein R, R, R, R, R, R, Rand m are as described herein, as modulators of the nicotinic acetylcholine receptors, particularly the &#x3b1;7 subtype, their tautomeric forms, stereoisomers, and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, and combinations thereof with suitable other medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and/or treatment of disorders such as Alzheimer's disease, mild cognitive impairment, and senile dementia. 

Pyrrole derivatives as alpha 7 NACHR modulators

Disclosed is a compound of formula (I), wherein R, R, R, R, R, R, Rand m are as described herein, as a modulator of nicotinic acetylcholine receptors particularly &#x3b1;7 subtype, its tautomeric forms, its stereoisomers, its pharmaceutically acceptable salts, its pharmaceutical composition, and its combinations with suitable medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like. 

Pyrrole derivatives as alpha 7 nAChR modulators

Disclosed are compounds of the formula (I), wherein R, R, R, R, R, R, Rand m are as described herein, as modulators of the nicotinic acetylcholine receptors, particularly the &#x3b1;7 subtype, their tautomeric forms, stereoisomers, and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, and combinations thereof with suitable other medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and/or treatment of disorders such as Alzheimer's disease, mild cognitive impairment, and senile dementia. 

Disclosed are an alpha 7 nAChR receptor modulator compound, 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1H-pyrrol-3-yljbenzenesulfonamide, its tautomeric form, its pharmaceutically acceptable salts, pharmaceutical compositions comprising the compound or a salt thereof, and a method of treating various diseases, disorders or conditions, for example, Alzheimer's disease, mild cognitive impairment, senile dementia, vascular dementia, dementia of Parkinson's disease, and attention deficit disorder.

4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1H-pyrrol-3-yl)benzenesulfonamide as alpha 7 nAChR modulator

The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel. 

Substituted pyrazole compounds as CRAC modulators

Substituted pyridine compounds as CRAC modulators

Disclosed is a compound of formula I: wherein Z, m and R-Rare as described herein, as a modulator of nicotinic acetylcholine receptors particularly the &#x3b1;7 subtype, in a subject in need thereof, as well as analogues, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereof, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogues. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.

Heteroaryl derivatives as alpha7 nAChR modulators

Disclosed is a compound of formula (I) wherein Y, Ring D, m and R-Rare as described herein, as a modulator of nicotinic acetylcholine receptors particularly the &#x3b1;7 subtype, in a subject in need thereof, as well as pharmaceutically acceptable salts, polymorphs, solvates, and isomers thereofs, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like. 

Thiazole derivatives as alpha 7 nAChR modulators

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R-R, R, R, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject. 

Tetrahydroquinazolinone derivatives as PARP inhibitors

Disclosed is a compound of formula (I) wherein 'a' and R-Rare as described herein, as a modulator of nicotinic acetylcholine receptors particularly the &#x3b1;7 subtype, in a subject in need thereof, as well as analogs, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereofs, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogs. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like. 

Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease

The present invention relates to compounds that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC and to processes for preparing these compounds. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC by these compounds.

Growing community of inventors

Pune, India

Neelima Sinha